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Figure 2. ISCs are expanded by IL-22 in vitro.
Figure 3. In vivo administration of F-652 (rhlL-22) rescues mice from GVHD.
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Landmark analyses at 3 and 6 months for subsequent FFS, NRM and survival.
FFS after 3 mos NRM after
3 mos
Surv
3 mo
NIH-calculated CR+PR vs. SD+PD P¼0.51 P¼0.55 P¼0.
Clinician-reported CR+PR vs. SD+PD HR 0.34,
95% CI 0.22-0.52,
P<0.001
P¼0.84 P¼0.
Clinician-reported Improvement vs.
Stable vs. Worsening
P<0.001 P¼0.57 P¼0.
Patient-reported Improvement vs.
Stable vs. Worsening
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One of the greatest challenges to research progress in
chronic graft-versus-host disease (GVHD) is lack of validated
response criteria for complete response (CR), partial
response (PR), stable disease (SD) and progressive disease
(PD). We compared four methods of assessing chronic GVHD
response (calculated response proposed in the 2005 NIH
chronic GVHD Consensus conference or clinician-reported
CR+PR vs. SD+PD, and clinician- or patient-reported
improvement, stability or worsening) for their ability to
predict three subsequent clinical outcomes at 3 and 6 mos:
failure free survival (FFS), deﬁned as survival without
addition of a new treatment, relapse or death; non-relapse
mortality (NRM); and survival. Data were derived from 575
adult patients in a prospective observational study
conducted by the Chronic GVHD Consortium at 9 centers.
342 (59%) were enrolled within 3 months (mos) of chronic
GVHD diagnosis. The median time to enrollment was 11.9
mos after transplant (range 2.9 - 294), median FU after
enrollment was 44 mos (range 0.9-76), and 149 (26%) have
died. At enrollment, 302 (53%) had moderate severity cGVHD
and 220 (38%) were classiﬁed as severe. Landmark analyses
were performed for patients who were alive and had not
failed at the three-month or six-month visit (Table). We
found that clinician-reported response at 3 mos wasival after
s
FFS after 6 mos NRM after 6 mos Survival after 6 mos
51 HR 0.73, 95%
CI 0.53-1.02,
p¼0.06
P¼0.24 HR 0.64, 95%
CI 0.39-1.02,
P¼0.06
47 HR 0.61, 95%
CI 0.44-0.85,
P¼0.004
P¼0.06 HR 0.55, 95%
CI 0.36-0.85,
P¼0.007
82 P¼0.28 P¼0.62 P¼0.60
36 P¼0.08 P¼0.33 P¼0.44
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response measure at 6 mos was predictive of subsequent OS
(p ¼ 0.007) and FFS (p¼0.004). Patient-reported changes
were associated with FFS after 3 mos but not with other
outcomes. No response measures predicted NRM. The fact
that FFS could be predicted by clinician- or patient-reported
response measures might reﬂect that clinicians and patients
control the main determinant of FFS, i.e., whether new sys-
temic immunosuppression is added. Incorporation of the
calculated CR + PR category did not signiﬁcantly change the
ability of the clinician-reported CR + PR to predict FFS or
survival after 6 months. We conclude that clinician-reported
CR+PR is highly associated with OS after 6 months, which is
independent of calculated CR+PR. Calculated response algo-
rithms might be improved by understanding and incorpo-
rating clinician judgment in assessing response.44
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Invariant natural killer T (iNKT) cells are potent regulators
of immune responses in humans (TCRa Va24-Ja18) and mice
(TCRa Va14-Ja18). We showed previously that host and
donor iNKT cells play a critical role for graft-versus-host
disease (GVHD) prevention and tolerance induction
following allogeneic hematopoietic cell transplantation
(HCT). In this study, we explored the role of adoptively
transferred third party CD4+ iNKT cells in a murine model of
allogeneic HCT across major histocompatibility barriers.
After 8 Gy total body irradiation BALB/c (H-2Kd) recipient
mice were transplanted with T cell-depleted bone marrowFigure 1. Representative bioluminescence images of BALB/c mice that
received Tcon alone or Tcon together with adoptively transferred third party
CD4+ iNKT cells. Tcon derived from FoxP3DTR/GFP/luc C57BL/6 mice with the
expression of the luciferase gene being under the control of the FoxP3
promoter.together with 1x106 CD4+/CD8+ T cells (Tcon) from C57BL/6
(H-2Kb) donor mice. Adoptive transfer of sorted (purity
>95%) 5x104 CD4+ iNKT cells from FVB/N (H2-Kq) third party
mice signiﬁcantly improved survival (p<0.001) while
retaining Tcon mediated graft-versus-tumor (GVT) effects
against BCL1 and A20 lymphoma cells (p¼0.002). Notably,
CD4+ iNKT cells from third party mice were as protective as
CD4+ iNKT cells from donor mice (p¼0.50). Consistently,
weight and GVHD scores improved in mice that received a
single injection of third party CD4+ iNKT cells as compared to
animals that received Tcon alone. Bioluminescence from
expanding luciferase expressing alloreactive Tcon was
signiﬁcantly decreased while showing a Th2-biased cytokine
proﬁle in animals treated with third party CD4+ iNKT cells
(p¼0.003). Interestingly, inhibition of Tcon proliferation
was comparable to animals that received CD4+ iNKT cells
from donor mice (p¼0.90). Although we found that third
party CD4+ iNKT cells were rejected by day +10 after allo-
geneic HCT, adoptive transfer resulted in a robust expan-
sion of luciferase expressing donor Treg using C57BL/6
FoxP3DTR/GFP/luc mice as a source of Tcon (p¼0.006, Figure 1).
Depletion of Treg from the graft by injection of diphtheria
toxin abrogated both donor Treg expansion and protection
from GVHD lethality through third party CD4+ iNKT cells. In
conclusion, low numbers of puriﬁed and adoptively trans-
ferred thirdparty CD4+ iNKTcells protect fromGVHD lethality
through activation and expansion of donor Tregwith retained
GVT effects. Despite the fact that iNKT cells are a rare cell
population, the in vivo activity of small numbers of cells and
feasibility of in vitro expansion provide the basis for clinical
translation.45
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Members of the sialic acid binding Igelike lectin (Siglec)
family, such as Siglec-G, have immunoreceptor tyrosine-
based inhibitory motifs (ITIM) regions that negatively
regulate innate immune activation induced by non-
infectious damage-associated molecular patterns (DAMPs).
The T-cell autonomous role of Siglec-G in modulating
immunity is not known. In order to examine the role of
Siglec-G on T cells we utilized the well-established MHC
disparate B6->BALB/c model of allogeneic BMT. BALB/c WT
mice were lethally irradiated (850cGy) and transplanted
on day 0 with 5x106 WT bone marrow from either
syngeneic WT-BALB/c or allogeneic WT-B6 along with
0.5x106CD90+T cells from WT or Siglec-G-/- B6 animals. The
allogeneic recipients receiving donor T cells from Siglec-G-/-
animals showed signiﬁcantly more severe GVHD and worse
survival compared to allogeneic WT-B6 animals (p¼0.01).
This increased mortality was also associated with greater
